Skip to content
Radio Logo
PodcastsLife SciencesBiotechTV - News

BiotechTV - News

BiotechTV
Latest episode

527 episodes

  • BiotechTV - News

    Jefferies London 2026: APOL1-mediated kidney disease affects over 1 million people in the United States - Maze Therapeutics hopes to deliver a solution

    11/18/2026 | 13 mins.
    CEO Jason Coloma describes the unmet need in this area - which affects younger people compared to most other chronic kidney conditions. He walks us through MZE829, which just completed enrollment the phase 2 HORIZON trial and will have data in early 2027.
  • BiotechTV - News

    Jefferies London: When Celgene's powerhouse myeloma treatments emerged, it wasn't known that they were protein degraders. With today's advances in science, C4 aims to have a best in class degrader

    11/18/2026 | 12 mins.
    President and CEO Andrew Hirsch describes the concept of protein degraders in general, and the paper that sparked the creation of C4 as a company. He discusses the company's registration intended trial, and another one in combination with a T-cell engager from Pfizer.
  • BiotechTV - News

    Jefferies London 2026: Zealand Pharma CEO Adam Steensberg gives an update on the company's amylin program and comments on recent data from its Boehringer partnered glucagon/GLP-1

    11/18/2026 | 14 mins.
    He shares his strong belief that for most people taking obesity medicines going forward, tolerability could be the most important factor of choice, which is amylin's strong suit.
  • BiotechTV - News

    Jefferies London 2026: Erasca is racing to be the next big story in the RAS space (in both pancreatic and lung) and believes it may have a best in class asset with high potency

    11/18/2026 | 13 mins.
    CEO Jonathan Lim descrbies the profile of ERAS-0015 and the data the company has derived up to this point. A phase 3 study is planned in 1st line pancreatic cancer in the early part of 2027 and two in lung later in the year. He also discusses combinations, including with Erasca's own KRAS inhibitor.
  • BiotechTV - News

    Jefferies London 2026: The phase 3 OPERA-01study of Olema's CERAN + SERD, palazestrant, is setting up to be one of biotech's key readouts and is quickly approaching and scheduled to read in 1Q27

    11/18/2026 | 11 mins.
    CEO Sean Bohen reminds us of the mechanism and the design of this monotherapy study, which is in the 2/3 line ER+/HER2 metastatic breast cancer setting. He also discusses why he believes the OPERA-02 study in 2nd line in combo with a CDK 4/6 can succeed where a competitor failed earlier this year.
More Life Sciences podcasts
About BiotechTV - News
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Podcast website

Listen to BiotechTV - News, Stuff To Blow Your Mind and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features
BiotechTV - News: Podcasts in Family